Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of product candidates derived from its lipid-crystal nano-particle, or cochleate, delivery technology platform. Its lead anti-fungal product candidate, MAT2203, safely and effectively delivers anti-infective therapies utilizing its proprietary LNC formulation technology. In addition, it is pursuing the development of MAT9001 which is a prescription-only omega-3 fatty acid-based composition, comprised primarily of EPA and DPA, under development for hypertriglyceridemia, which has shown superiority versus Vascepa (icosapent ethyl) in reducing serum triglycerides, Total- and Non-HDL-Cholesterol, apolipoproteins, and PCSK9 levels.